Holen Sie sich die Stockscreener-App
59.91
0.32%
0.19
Handel nachbörslich:
60.05
0.14
+0.23%
Schlusskurs vom Vortag:
$59.72
Offen:
$55.8
24-Stunden-Volumen:
830.28K
Relative Volume:
1.11
Marktkapitalisierung:
$4.28B
Einnahmen:
$58.89M
Nettoeinkommen (Verlust:
$-240.88M
KGV:
-19.33
EPS:
-3.1
Netto-Cashflow:
$-239.96M
1W Leistung:
-3.29%
1M Leistung:
+3.47%
6M Leistung:
+69.81%
1J Leistung:
+27.28%
1-Tages-Spanne:
$55.66
$61.58
1-Wochen-Bereich:
$55.66
$63.36
52-Wochen-Spanne:
$19.45
$63.96
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Vergleichen Sie KYMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
59.91 | 4.27B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Fortgesetzt | Guggenheim | Buy |
| 2025-10-24 | Bestätigt | B. Riley Securities | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus
Is Kymera Therapeutics Inc. stock supported by innovation pipeline2025 Dividend Review & Real-Time Market Trend Scan - newser.com
Kymera Therapeutics Reports Q3 2025 Financial Results - TipRanks
Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges - TipRanks
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Cullinan Management (CGEM) and Idexx Laboratories (IDXX) - The Globe and Mail
Kymera outlines mid-2027 topline readout for KT-621 Phase IIb study as pipeline advances and Gilead partnership grows - MSN
Transcript : Kymera Therapeutics, Inc., Q3 2025 Earnings Call, Nov 04, 2025 - MarketScreener
Kymera Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Oppenheimer raises Kymera Therapeutics stock price target ahead of Phase 1b readout - Investing.com Canada
Earnings call transcript: Kymera Therapeutics Q3 2025 misses EPS expectations - Investing.com Philippines
Kymera Q3 2025 slides reveal strong cash position despite earnings miss - Investing.com
Kymera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update - Investing News Network
Earnings Flash (KYMR) Kymera Posts Q3 Loss $0.94 a Share, vs. FactSet Est of $0.68 Loss - MarketScreener
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q3 Revenue $2.8M, vs. FactSet Est of $23.3M - MarketScreener
Kymera Therapeutics Inc Q3 2025 Earnings: EPS of -$0.94 Misses E - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Guggenheim - MarketBeat
Kymera Therapeutics (NASDAQ: KYMR) completes AD Phase 1b dosing, starts Phase 2b trial - Stock Titan
Kymera Therapeutics Q3 2025 Earnings Preview - MSN
Pattern recognition hints at Kymera Therapeutics Inc. upsideJuly 2025 Opening Moves & Expert Curated Trade Setups - newser.com
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - Investing News Network
Guggenheim Assumes Buy Rating for Kymera Therapeutics (KYMR) | K - GuruFocus
Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For - GuruFocus
How to read the order book for Kymera Therapeutics Inc.Portfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times
Guggenheim assumes coverage on Kymera stock with Buy rating, $90 target - Investing.com Canada
Kymera Therapeutics (NASDAQ: KYMR) to join 5 November investor conferences; webcasts - Stock Titan
How analysts rate Kymera Therapeutics Inc. stock today2025 Year in Review & Stock Portfolio Risk Control - newser.com
What valuation multiples suggest for Kymera Therapeutics Inc. stock2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com
AlphaQuest LLC Acquires New Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
34,797 Shares in Kymera Therapeutics, Inc. $KYMR Bought by Moody Aldrich Partners LLC - MarketBeat
Is Kymera Therapeutics Inc. stock attractive for ETFsWeekly Stock Report & Weekly Breakout Opportunity Watchlist - newser.com
Jennison Associates LLC Acquires 272,739 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $1,829,700.00 in Stock - MarketBeat
How hedge fund analytics apply to Kymera Therapeutics Inc. stockJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Is Kymera Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - newser.com
Kymera Therapeutics Insider Sold Shares Worth $1,829,737, According to a Recent SEC Filing - MarketScreener
KYMR insider trade: CEO option exercise and matching share sales - Stock Titan
Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases - Yahoo Finance
How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA - Yahoo Finance
Is Kymera Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Earnings & Low Volatility Stock Recommendations - fcp.pa.gov.br
Kymera Therapeutics to Announce Q3 2025 Financial Results and Host Video Conference on November 4, 2025 - Quiver Quantitative
Kymera Therapeutics (NASDAQ: KYMR) to report third quarter 2025; webcast at 8:30 a.m. ET - Stock Titan
What technical charts say about Kymera Therapeutics Inc. stockJuly 2025 Summary & Community Verified Trade Signals - Fundação Cultural do Pará
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):